As we identified TFAP2A was a potential diagnostic biomarker for RB, we then designed the primers and probe for the methylation specific PCR (MSP) in this region to validate clinical utility of TFAP2A for RB diagnosis. Here, TFAP2A is linked to retinoblastoma.